NCT01903785

Salbutamol, Pharmacogenetics and Breathing Mechanics

The Pharmacogenetic Effects of Inhaled Salbutamol on Breathing Mechanics and Cycling Performance

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 94 (actual)
• Sponsor: University of British Columbia · Academic / Other
• Sex: All
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Athletes using asthma medications called β2-agonists win a disproportionately high number of medals at Olympic Games. Due to a large variety in the genes that affect how individuals respond to β2-agonists, the investigators will look at variations in the genetic response to these medications by dividing athletes into high-responders and low-responders. The investigators will then compare athletic performance after the inhalation of β2-agonists to placebo. Furthermore, the investigators will analyze the effect of β2-agonists on breathing mechanics. Due to differences in their anatomy females may decrease the energy needed for breathing during high-intensity exercise to a greater extent compared to male athletes after the inhalation of β2-agonists.

Conditions

• Bronchoconstriction
• Inhaled Salbutamol
• Cycling Performance

Interventions

Type	Name	Description
DRUG	Salbutamol	60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
DRUG	Placebo

Timeline

• Start date: 2013-05-01
• Primary completion: 2014-12-01
• Completion: 2016-08-01
• First posted: 2013-07-19
• Last updated: 2016-11-02

Locations

1 site across 1 country: Canada